Overview
Yuviwel (navepegritide) is a once‑weekly, subcutaneous C‑type natriuretic peptide (CNP) analog approved by the U.S. Food and Drug Administration in February 2026 to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses.[1,2] Developed by Ascendis Pharma as TransCon CNP, Yuviwel is a PEGylated prodrug that releases native CNP over several days, enabling continuous activation of natriuretic peptide receptor‑B (NPR‑B) and inhibition of overactive FGFR3 signaling in the growth plate.[1–3]
The approval was granted under the Accelerated Approval Program based primarily on improvement in annualized growth velocity in the pivotal ApproaCH randomized clinical trial, supplemented by data from a phase 2 dose‑finding study and open‑label extension follow‑up.[1,3] Yuviwel carries no boxed warning or REMS requirement but includes a warning about the risk of low blood pressure and is not recommended in patients with moderate or severe renal impairment.[1]
In a landscape previously dominated by daily CNP analog therapy with vosoritide, Yuviwel represents the first once‑weekly, continuous‑exposure CNP approach, potentially reducing treatment burden while demonstrating benefits in linear growth, skeletal alignment, and selected quality‑of‑life measures.[2,3,5,6]
Core FDA Documentation and Regulatory Milestones
| Item | Details | Source |
|---|---|---|
| Application type | NDA 219164 (section 505(b)(1), new molecular entity – CNP analog prodrug) | accessdata.fda+1 |
| Proprietary name | Yuviwel | accessdata.fda+1 |
| Nonproprietary name | navepegritide | accessdata.fda+1 |
| Dosage form | Lyophilized powder for injection in single‑dose vials (1.3 mg, 2.8 mg, 5.5 mg) | accessdata.fda |
| Route of administration | Subcutaneous injection (once weekly) | accessdata.fda |
| Initial U.S. approval date | February 27, 2026 | accessdata.fda+2 |
| Latest label revision | Revised 2/2026 on FDA label | accessdata.fda |
| Sponsor / manufacturer | Ascendis Pharma Growth Disorders A/S; manufactured for Ascendis Pharma Endocrinology, Inc. | accessdata.fda+1 |
| FDA‑approved use at launch | Increase linear growth in pediatric patients 2 years and older with achondroplasia and open epiphyses | accessdata.fda+1 |
| Regulatory pathway | Accelerated Approval based on improvement in annualized growth velocity | accessdata.fda+2 |
| Special designations | Orphan Drug designation, Priority Review, Rare Pediatric Disease Priority Review Voucher at approval | primetherapeutics+3 |
Disease Background and Treatment Landscape
Achondroplasia is the most common genetic cause of disproportionate short stature and skeletal dysplasia, driven primarily by gain‑of‑function variants in the fibroblast growth factor receptor 3 (FGFR3) gene that impair endochondral ossification.[4] Birth prevalence is estimated at roughly 1 in 20,000–25,000 live births, and achondroplasia accounts for the majority of cases of disproportionate short stature.[4,7] Beyond short limb length, affected individuals experience substantial morbidity, including foramen magnum stenosis, spinal canal narrowing, thoracolumbar kyphosis, genu varum, obstructive sleep apnea, recurrent otitis media with hearing loss, and chronic musculoskeletal pain.[4,7]
Historically, management has relied on multidisciplinary surveillance and symptomatic interventions such as neurosurgical decompression, orthopedic corrective procedures, hearing interventions, and treatment of sleep‑disordered breathing, guided by expert consensus.[4, 7] Limb‑lengthening procedures may increase adult height but are intensive and associated with significant physical and psychosocial burden.[4]
The therapeutic landscape changed with the accelerated approval of vosoritide (Voxzogo), an engineered CNP analog administered as a once‑daily subcutaneous injection that increased annualized growth velocity by approximately 1.5–1.6 cm/year versus placebo in phase 3 trials.[5,6] International consensus guidelines now provide structured recommendations for implementing and monitoring vosoritide therapy, but real‑world uptake has been limited in some regions by daily injection burden, cost, and variability in payer coverage.[5, 7]
Yuviwel enters this landscape as a second CNP‑based therapy, offering once‑weekly dosing and continuous exposure of native CNP with trial data indicating improvements in growth velocity, lower‑limb alignment, and patient‑reported physical functioning.[2,3] Its accelerated approval underscores both the high unmet need in pediatric achondroplasia and the requirement for confirmatory evidence on long‑term clinical outcomes such as surgery rates and neurologic or respiratory complications.[1,3]
Mechanism of Action
Achondroplasia pathophysiology centers on gain‑of‑function mutations in FGFR3 that lead to excessive activation of MAPK/ERK signaling in growth‑plate chondrocytes, inhibiting proliferation and differentiation and impairing endochondral bone formation.[4] C‑type natriuretic peptide (CNP) is an endogenous paracrine mediator that counter‑balances FGFR3 signaling by activating NPR‑B, a guanylyl cyclase receptor that increases cyclic guanosine monophosphate (cGMP) and downstream protein kinase G activity, ultimately inhibiting MAPK pathway signaling.[1,4,6]
Navepegritide consists of native CNP(89‑126) transiently conjugated to two 20 kDa methoxy‑PEG chains via a proprietary TransCon linker, which increases its apparent molecular weight and slows systemic release after subcutaneous administration.[1] Auto‑cleavage of the linker over several days releases unmodified CNP that retains normal binding affinity and activity at NPR‑B.[1] At the approved 0.1 mg/kg/week dose, pharmacokinetic modeling suggests steady state after approximately three weekly injections, with an exposure half‑life for released CNP of about 5 days, supporting near‑continuous receptor engagement across the dosing interval.[1]
Sustained NPR‑B activation leads to tonic elevation of cGMP in growth‑plate chondrocytes and inhibition of overactive FGFR3‑MAPK signaling, restoring a more physiologic balance of proliferation and differentiation and increasing longitudinal bone growth.[1,3] These mechanistic effects align with observed increases in annualized growth velocity and improvements in skeletal parameters in clinical trials.[1,3]
From a safety standpoint, systemic vasodilation and hypotension are theoretical concerns with CNP‑based therapies and were observed as transient blood pressure reductions during vosoritide development, prompting close blood pressure monitoring and exclusion of subjects with significant cardiovascular disease in navepegritide trials.[1,6] The Yuviwel label includes a warning for risk of low blood pressure, but symptomatic hypotension and treatment‑related hypotensive events were not reported in ApproaCH, and asymptomatic hypotension occurred at low and similar rates in navepegritide and placebo arms.[1,3]
Simple analogy for general readers:
Once a week, Yuviwel delivers a steady “anti‑brake” signal that counteracts the overactive growth brake in achondroplasia so growth plates can function more normally.[1,3]
Clinical Evidence
ApproaCH Trial (Phase 2b, NCT05598320)
ApproaCH was a multinational, phase 2b, double‑blind, placebo‑controlled randomized clinical trial evaluating the efficacy and safety of once‑weekly navepegritide in children with achondroplasia.[3] Children aged 2–11 years with genetically confirmed achondroplasia, open epiphyses, and no prior exposure to growth‑promoting agents were randomized 2:1 to navepegritide 100 µg/kg/week or placebo for 52 weeks, stratified by age group and sex.[1,3]
The primary endpoint was annualized growth velocity at week 52, assessed via standardized stadiometry and adjudicated in a blinded manner.[3] Key secondary and exploratory endpoints included changes in achondroplasia‑specific and CDC‑based height z‑scores, radiographic measures of spinal and lower‑limb morphometry, and health‑related quality of life using the Achondroplasia Child Experience Measures instrument.[1,3]
Primary efficacy outcome
- Annualized growth velocity at week 52:
- Navepegritide: least‑squares (LS) mean 5.9 cm/year.
- Placebo: LS mean 4.4 cm/year.
- LS mean difference: 1.49 cm/year (95% CI 1.05–1.93; p < 0.001).[1,3]
Height z‑scores
- Achondroplasia‑specific height z‑score: LS mean change +0.28 to +0.30 with navepegritide versus approximately 0.0 with placebo, with an LS mean difference of about 0.28–0.30 (p < 0.0001).[1,3]
- CDC‑based z‑score: LS mean difference ≈0.3 (95% CI 0.1–0.5), analyzed outside the prespecified multiplicity strategy and therefore interpreted descriptively.[1]
Subgroup analyses (exploratory)
- Children <5 years: AGV LS mean difference ≈1.0 cm/year favoring navepegritide.
- Children ≥5 years: AGV LS mean difference ≈1.8 cm/year, suggesting greater benefit in older children, although these subgroup findings are exploratory.[1,3]
Responder‑based outcomes (e.g., proportion achieving a predefined AGV increase) necessary to calculate a conventional number needed to treat are not reported and therefore cannot be derived.[1,3]
Skeletal Morphometry and Functional Outcomes
Exploratory radiographic endpoints in ApproaCH assessed lower‑limb alignment and spinal parameters relevant to long‑term orthopedic risk.[3] At week 52, compared with placebo, navepegritide:
- Reduced tibial‑femoral angle (LS mean difference about –1.8 degrees; p ≈ 0.009).
- Reduced mechanical axis deviation (difference ≈ –2.8 mm; p ≈ 0.006).
- Reduced fibula:tibia length ratio (difference ≈ –0.016; p ≈ 0.0001), consistent with partial normalization of fibular overgrowth associated with genu varum.[3]
Savarirayan et al. also reported increased interpedicular distance at L1 in the navepegritide group, suggesting potential favorable effects on spinal canal dimensions, though the clinical implications for stenosis risk remain to be defined.[3]
In children younger than 5 years, navepegritide improved Achondroplasia Child Experience Measures–Physical Functioning scores versus placebo, indicating better physical functioning and daily activity performance over 52 weeks.[3]
Dose‑Finding and Long‑Term Extension (Trial 2, NCT04085523)
A preceding dose‑finding study evaluated multiple once‑weekly navepegritide doses (0.006–0.1 mg/kg/week) over 52 weeks, followed by an open‑label extension in which all participants received 0.1 mg/kg/week.[1,3] The 0.1 mg/kg/week dose was selected for pivotal development based on efficacy and safety, and extension data support maintenance of growth velocity improvements over at least 2 years without new safety signals.[1,3]
Long‑term outcomes regarding the need for orthopedic or neurosurgical procedures, respiratory complications, and adult stature have yet to be fully characterized.[3, 7]
Safety Profile and Risk Management
Overall Tolerability
Across ApproaCH and supporting phase 2 studies, Yuviwel demonstrated a generally favorable safety profile.[1,3] Approximately 99% of adverse events were mild or moderate, and no deaths or treatment‑related serious adverse events were reported.[3] No adverse events led to treatment discontinuation or study withdrawal.[3]
The most common adverse reactions (≥5% and ≥2% higher than placebo) were vomiting, injection‑site reactions, pain in extremity, and nausea.[1] Rates of treatment‑related adverse events were similar in navepegritide and placebo arms.[3]
Hemodynamic Effects
Given the vasodilatory potential of CNP‑based therapies, blood pressure was closely monitored in navepegritide trials, and subjects with hemodynamically significant cardiovascular disease were excluded.[1,6] The Yuviwel label includes a warning for risk of low blood pressure and advises patients and caregivers to seek medical attention for symptoms such as dizziness, fatigue, or nausea.[1]
In ApproaCH, asymptomatic hypotension events were rare and occurred at low, similar rates in navepegritide and placebo groups, with no events judged treatment‑related and no symptomatic hypotension reported.[3] Routine blood pressure monitoring and careful review of concomitant antihypertensive therapy remain prudent in clinical practice.[1,3]
Injection‑Site Reactions and Dermatologic Effects
Injection‑site reactions (erythema, swelling, bruising, pruritus, pain, vesicles, edema) were among the most frequent adverse reactions but were typically mild and self‑limiting, with only modestly higher incidence than placebo.[1,3] Hypertrichosis localized to injection sites or generalized to limbs, back, or shoulders occurred in a small proportion of navepegritide‑treated participants; rotation of injection sites is recommended to reduce local changes.[1]
Immunogenicity
Anti‑drug antibodies developed in a subset of patients treated with navepegritide 0.1 mg/kg/week for up to 3 years, but were usually low‑titer and transient with no clear impact on pharmacokinetics, efficacy, or safety.[1] Because of assay limitations, the neutralizing capacity of these antibodies remains uncertain, and the FDA has mandated ongoing immunogenicity assessment in post‑marketing studies.[1]
Special Populations
Yuviwel is not recommended in patients with moderate or severe renal impairment (eGFR < 60 mL/min/1.73 m²), while patients with mild renal impairment (eGFR ≥ 60) use standard dosing.[1] Pharmacokinetics in hepatic impairment have not been studied, and no dose recommendations are provided.[1] Safety and effectiveness are not established in children younger than 2 years; the approved indication covers patients ≥2 years with open epiphyses.[1]
No human data are available in pregnancy or lactation; animal studies up to several‑fold human exposures found no embryo‑fetal toxicity, but use during pregnancy or breastfeeding should be avoided unless benefits clearly outweigh potential risks.[1] Discontinuation is recommended once epiphyseal closure is confirmed.[1]
Dosing and Practical Use
Standard Regimen
Yuviwel is administered once weekly by subcutaneous injection at a weight‑based dose approximating 0.1 mg/kg/week; the Prescribing Information includes a detailed dosing table linking body‑weight bands to fixed milligram doses (0.88–8.8 mg).[1] Treatment is continued while epiphyses remain open, with dose adjustment as weight increases and discontinuation at epiphyseal closure.[1]
Adjustments and Special Situations
Yuviwel should not be used in patients with moderate or severe renal impairment; no dose adjustment is required for mild renal impairment.[1] For patients transitioning from daily vosoritide, Yuviwel can be started the day after the last daily CNP analog dose, ensuring at least 5 days between weekly injections.[1,6] If a weekly dose is missed, it may be administered up to 2 days before or after the scheduled day; if more than 2 days late, the dose should be skipped and therapy resumed on the next scheduled day, maintaining at least 5 days between injections.[1]
Preparation and Administration
The lyophilized powder is reconstituted with the supplied Sterile Water for Injection after bringing both vial and diluent to room temperature.[1] The vial is shaken up and down for 15 seconds and allowed to stand for 5 minutes; it should not be swirled or rolled.[1] The dose is administered subcutaneously into the abdomen or thigh; caregivers may also use the buttocks or back of the upper arm in young children, rotating injection sites to minimize local reactions.[1]
For doses requiring more than 1 mL injection volume, two kits and two injections at separate sites are used to deliver the full weekly dose.[1] After reconstitution, the solution may be stored at room temperature (≤30 °C) for up to 4 hours, then must be discarded; unreconstituted vials are stored refrigerated but can be kept at room temperature for up to 6 months within the expiry date.[1]
Patient‑Centered Considerations
Eligibility in Practice
Candidates for Yuviwel should have genetically confirmed achondroplasia, open epiphyses, and no other major conditions that independently impair growth, such as severe chronic systemic disease or malnutrition.[3,4] Children with moderate or severe renal impairment, significant cardiovascular disease, or severe untreated sleep apnea were not represented in the pivotal trials and warrant particularly cautious risk–benefit assessment.[1,3]
Quality of Life and Treatment Burden
ApproaCH suggests that gains in linear growth and skeletal alignment translate into measurable improvements in physical functioning, especially among younger children, as captured by Achondroplasia Child Experience Measures.[3] Longer‑term observational data are needed to clarify impacts on pain, independence, requirement for orthopedic procedures, and psychosocial outcomes.[4,7]
A once‑weekly injection schedule may be more compatible with family routines than daily injections and could support adherence, but formal comparative adherence data versus vosoritide are not yet available.[2,3,6] Shared decision‑making should address realistic expectations (incremental height gains rather than normalization), uncertainties about long‑term outcomes, and financial considerations including payer coverage and available assistance programs.[5, 7]
Regulatory and Post‑Marketing Journey
TransCon CNP (navepegritide) progressed through development as a targeted therapy for pediatric achondroplasia, culminating in FDA review under the accelerated approval framework.[2,3] Based on positive phase 2/3 data showing significant improvements in annualized growth velocity and supportive safety findings, the FDA granted accelerated approval for Yuviwel on 27 February 2026 for increasing linear growth in children ≥2 years with achondroplasia and open epiphyses, and issued a Rare Pediatric Disease Priority Review Voucher.[1–3]
Post‑marketing commitments include further characterization of immunogenicity, with particular focus on neutralizing antibodies, and confirmatory trials to verify and describe clinical benefit beyond annualized growth velocity, such as effects on orthopedic surgery requirements, neurologic complications, and long‑term functional outcomes.[1,3] As of early 2026, no major label changes such as new boxed warnings or expanded indications have been reported.[1,2]
FAQs
-
Who is Yuviwel indicated for?
Yuviwel (navepegritide) is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia and open epiphyses, under accelerated approval based on improvement in annualized growth velocity.
-
How is Yuviwel given and how often?
Yuviwel is administered once weekly as a subcutaneous injection, with the dose selected from a weight‑based dosing table in the Prescribing Information; doses are adjusted periodically as the child grows. Caregivers are trained to reconstitute the vial and inject into rotating sites such as abdomen or thigh.
-
What are the most common side effects of Yuviwel?
The most common adverse reactions (≥5%) are vomiting, injection‑site reactions (redness, itching, discoloration, swelling, bruising, pain, blistering), pain in extremity, and nausea. Most events in trials were mild or moderate in severity.
-
Does Yuviwel replace other achondroplasia care (surgeries, sleep apnea management, etc.)?
No. Growth‑modulating therapy does not remove the need for ongoing surveillance and management of complications such as foramen magnum stenosis, spinal stenosis, otitis media, or sleep apnea; multidisciplinary care remains essential.
-
How quickly might families see an effect on growth?
In the ApproaCH trial, the treatment effect on annualized growth velocity was assessed over 52 weeks, with an average gain of about 1.5 cm/year versus placebo at one year; growth is monitored over months rather than weeks in clinical practice.
-
Is Yuviwel recommended for all children with achondroplasia?
Use should be individualized; factors include age (≥2 years), open epiphyses, renal function (not recommended in moderate/severe impairment), comorbidities, family preferences, and willingness to accept long‑term therapy with still‑evolving outcome data.
-
Can a child switch from daily vosoritide to once‑weekly Yuviwel?
The Yuviwel label allows initiation the day after the last dose of a daily CNP analog, maintaining at least 5 days between Yuviwel injections, but any switch should be supervised by a pediatric endocrinologist familiar with both products.
Is Yuviwel available for your patients in India?
Yuviwel is currently FDA‑approved in the United States; Indian marketing approval and local availability have not yet been announced. For updates on DCGI approval, import options, and access pathways, follow Laafon’s regulatory trackers or contact your local Ascendis/partner representative when announced.
Conclusion and Forward Look
Yuviwel (navepegritide) provides pediatric patients with achondroplasia and their families with a once‑weekly, targeted therapy that has demonstrated clinically meaningful gains in annualized growth velocity and early improvements in skeletal alignment and physical functioning, with a generally favorable safety profile dominated by mild gastrointestinal and injection‑site events.[1–3] Its accelerated approval highlights both the strength of surrogate endpoint data and the necessity for continued evaluation of long‑term safety and real‑world effectiveness.[1–3]
In clinical practice, Yuviwel is likely to be considered alongside daily vosoritide, with therapy selection individualized based on age, comorbidities, family preferences regarding injection frequency, local experience, and payer coverage.[5–7] Ongoing extension studies, registries, and confirmatory trials will be crucial for determining whether early improvements in growth and alignment translate into reduced surgical burden, improved neurologic and respiratory outcomes, and better health‑related quality of life across the lifespan.[3,4,7]
Disclaimer: This article is for informational purposes only and does not replace the full Prescribing Information or professional medical advice. Healthcare professionals should consult the current Yuviwel Prescribing Information and relevant clinical guidelines before making treatment decisions.[1,5]
References
- U.S. Food and Drug Administration. YUVIWEL (navepegritide) for injection, for subcutaneous use. Prescribing Information, 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
- Ascendis Pharma. FDA approves once‑weekly YUVIWEL (navepegritide) for children with achondroplasia aged 2 years and older. Press release, 26 Feb 2026. Available from: https://www.globenewswire.com/news-release/2026/02/27/3246848/0/en/FDA-Approves-Once-Weekly-YUVIWEL-navepegritide-for-Children-with-Achondroplasia-Aged-2-Years-and-Older.html
- Savarirayan R, et al. Once‑Weekly Navepegritide in Children With Achondroplasia (ApproaCH Trial). JAMA Pediatrics. 2025. Available from: https://pubmed.ncbi.nlm.nih.gov/41247754/
- McDonald EJ, Chamarthi VS, Karsonovich T. Achondroplasia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559263/
- Hoover‑Fong J, et al. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol. 2025;21(5):314‑324. Available from: https://pure.johnshopkins.edu/en/publications/international-consensus-guidelines-on-the-implementation-and-moni/
- BioMarin Pharmaceutical Inc. VOXZOGO (vosoritide) for injection, for subcutaneous use. Prescribing Information, revised 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214938s002lbl.pdf
- Kuo V, et al. Clinical and economic burden of achondroplasia in the United States: results from a retrospective, observational study. Orphanet J Rare Dis. 2025;20:XX. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11869590/
